The strategy's results, tracked between 2022 and 2024 across 48 participating member companies representing a 96% participation rate among relevant members, show carbon emissions falling 26%, water use down 2.9%, and energy consumption down 4.5%, achieved despite a 5.8% increase in production and continued employment growth over the same period, a genuine decoupling of output from environmental impact rather than improvement driven simply by lower activity levels. Renewable sources now supply over two-thirds of the sector's electricity, including on-site generation, though BPCI itself flags that further Scope 1 and 2 decarbonisation faces real constraints around grid capacity, supply reliability and access to affordably priced renewable electricity, an honest acknowledgment that the easier wins may already have been captured.

The most recent 2026 edition of the same report shows the trend continuing, with pharmaceutical exports up 29% to €99.9 billion in 2024 alongside a 30.5% reduction in electricity-related CO2 emissions and a 23% cut in volatile organic compound emissions, though BPCI also acknowledges a widening hazardous waste gap linked to growth in more complex active pharmaceutical ingredient production, a reminder that decoupling growth from environmental impact is not automatic across every metric even where the headline trend is positive.

#ChemicalSMEs #IndustrialDecarbonisation #SustainableChemistryFunding